Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 7, 2019

Modified Ketogenic Diet Therapy for Relapsing Multiple Sclerosis: Patient-Reported Outcomes (P3.2-044)

J. Nicholas Brenton, Brenda Banwell, A. G. Bergqvist, Diana Lehner-Gulotta, Lauren Gampper, Emily Leytham, Myla Goldman
First published April 16, 2019,
J. Nicholas Brenton
1Neurology, University of Virginia Health System Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda Banwell
2Childrens Hospital of Philadelphia Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. G. Bergqvist
3The Children’s Hospital of Philadelphia Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Lehner-Gulotta
1Neurology, University of Virginia Health System Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Gampper
1Neurology, University of Virginia Health System Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Leytham
1Neurology, University of Virginia Health System Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myla Goldman
4University of Virginia Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Modified Ketogenic Diet Therapy for Relapsing Multiple Sclerosis: Patient-Reported Outcomes (P3.2-044)
J. Nicholas Brenton, Brenda Banwell, A. G. Bergqvist, Diana Lehner-Gulotta, Lauren Gampper, Emily Leytham, Myla Goldman
Neurology Apr 2019, 92 (15 Supplement) P3.2-044;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To report the multiple sclerosis (MS) patient experience after completion of a 6 month trial of a modified ketogenic diet.

Background: Dietary intake influences an individual’s immune profile and response. The impact of diet in MS is clinically meaningful, with evidence supporting an association between diet and disability. We have previously reported evidence of safety and adherence of ketogenic diets (KDs) in relapsing-remitting MS (RRMS) patients, with improvements in fatigue, depression, and disability metrics.

Design/Methods: Twenty patients with a diagnosis of RRMS were enrolled. Subjects were educated in-person by a trained dietitian on how to adhere to a modified KD (i.e. modified Atkins or KDMAD). Adherence to diet was objectively monitored by daily urine ketone testing. Clinical and patient-reported outcome measures were obtained at baseline (pre-diet) and after 6 months of treatment. A patient-experience survey was completed at the time of diet trial completion.

Results: Of the 20 subjects enrolled at baseline, two subjects were lost to follow-up. From the remaining 18 subjects, over half had previously attempted a diet for their MS. Upon completing the 6 month trial of KDMAD, 56% of subjects planned to continue on strict KDMAD after trial completion. All 18 subjects would recommend KDMAD to a colleague. The most common patient-perceived benefits of KDMAD included weight loss (83%), improved fatigue (72%), improved exercise habits (55.5%), improved stamina (50%), and reduced MS symptoms (45%). The most common side effects experienced on KDMAD included constipation (28%), menstrual irregularities (22%), and diarrhea (17%).

Conclusions: The KDMAD is a feasible diet for RRMS patients and provides multiple patient-perceived benefits that are clinically-relevant to MS subjects. As the majority of our subjects plan to continue on KDMAD, longitudinal clinical and laboratory data collection is ongoing.

Disclosure: Dr. Brenton has nothing to disclose. Dr. Banwell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Bergqvist has nothing to disclose. Dr. Lehner-Gulotta has nothing to disclose. Dr. Gampper has nothing to disclose. Dr. Leytham has nothing to disclose. Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Celgene, Sanofi Genzyme, Novartis Pharmaceutical, RxMx, and Teva Neuroscience. Dr. Goldman has received research support from MedDay, Novartis , NIH, National MS Society, and PCORI.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise